T-cells expressing a chimeric antigen receptor (CAR) recognizing the CD19 antigen have shown high early response rates in high-risk B acute lymphoblastic leukaemia (B-ALL) [1]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.